2005 issue 1


Volume 21, issue 1


Trombolysis in acute ischemic stroke

Adam Kobayashi1,2, Anna Członkowska1,2
1. Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej Akademii Medycznej w Warszawie
2. II Klinika Neurologiczna Instytutu Psychiatrii i Neurologii w Warszawie
Farmakoterapia w Psychiatrii i Neurologii, 2005, 1, 5-18
Keywords: stroke, therapeutic window, recombinant tissue plasminogen activator


Contemporary treatment of acute ischemic stroke focuses on drugs inducing early reperfusion of occluded arteries leading blood to the brain. Thrombolysis with recombinant tissue plasminogen activator (rt-PA, alteplase) is the only agent proved to be effective in clinical trials and having a considerably low rate of adverse effects if introduced within 3 hours of stroke symptom onset. Recently studies on expanding the therapeutic window, what could result in increasing the number of treated patients and inducing rt-PA efficacy are being performed. Clinical trials and our experience confirm it's higher efficacy compared to other known stroke treatments.